Table 1.
Clinical and laboratory parameters of patients with Clostridium difficile infection and correlation with fecal Calprotectin levels
| Parameter | Mean (percent/range) |
fc levels (μg/g), mean (range) |
P -value for correlation with fc levels |
|---|---|---|---|
| Antibiotic-reduced susceptibility | |||
| Metronidazole | 3 (10.3 %) | Reduced susceptibility to Metronidazole: 177.7 (46–287) | 0.5474 |
| Metronidazole susceptible 349 (21–932) | |||
| Vancomycin | 5 (17.2 %) | Reduced susceptibility to Vancomycin 336.8 (113–932) | 0.7316 |
| Vancomycin susceptible 330.3 (21–912) | |||
| Gender | |||
| Male | 15 (51.7 %) | 340.8 (48–932) | |
| Female | 14 (48.3 %) | 321.4 (21–911) | 0.7622 |
| Age (years) | 64.5 (17–95) | 0.2764 | |
| Functional status | |||
| Independent | 14 (48.3 %) | 316.8 (21–932) | |
| Debilitated | 15 (51.7 %) | 45.1 (46–911) | 0.6815 |
| CDI acquisition | |||
| Community | 10 (34.5 %) | 273.6 (21–911) | |
| Nursing home | 3 (10.3 %) | 234.7 (21–411) | |
| Hospital | 16 (55.2 %) | 385.8 (46–932) | 0.5678 |
| Body temperature (°C) | 37.0 (36–39.4) | 0.8772 | |
| Peripheral white blood cell count (/μl) | 13,363 (3070–43,210) | 0.0007 | |
| Creatinine(g/dL) | 1.3 (0.2–6.7) | 0.2 | |
| Disease recurrence in 30 days | 10 (34.5 %) | Disease recurrence 284.7 (46–800) | 0.6662 |
| No recurrence 356.1 (21–932) | |||
| 30 day mortality | |||
| Yes | 2 (6.9 %) | 579.5 (248–911) | |
| No | 27 (93.1 %) | 313.3 (21–932) | 0.2550 |
| Clostridium severity score index | 2.17 (1–6) | 0.0633 |